Benjamin Podvin

Clinical pathologist in Hematology. Translational researcher. PhD student.

[nizar jacques bahlis @NBahlis]

Talquetamab–Daratumumab in Relapsed or Refractory Myeloma | New England Journal of Medicine https://t.co/CRkQJpYqit . Another bispecific , now targeting GPRC5D, giving anti-BCMA CAR the nudger in 1-3 prior lines of therapy space

[Daniel Auclair @AuclairDan]

Proud to represent the latest work from an amazing team on a new ultrasensitive WGS clinical assay that can be done on marrow or blood. Come see it, PF787 #EHA26 #EHA2026 #mmsm

[Dan Landau @landau_lab]

Exciting breakthrough technology from the lab, now live in @CellCellPress ! Instead of cutting the genome where proteins bind (e.g., Cut&Tag), D&D-seq scars the DNA with a deaminase, allowing single cell genome mapping of TFs and chromatin remodellers!

[nizar jacques bahlis @NBahlis]

Teclistamab in Data refractory patients Majestec-9. Impressive data. Real competitor for CART #ASCO2026 https://t.co/jUu8G3S2qz

[Jun Qi Lab @JunQiLab]

Our collaborative work with @IrenemGhobrial on targeting transcription factor IRF4 is now online @nchembio. It is so exciting that we discovered an IRF4 binder & a selective IRF4 degrader that can interrupt MM cell growth. Congrats @10mM_Mike & all authors https://t.co/RJFu6wqJsU

[Daniel Auclair @AuclairDan]

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights #mmsm

https://t.co/TCmMFt6mSh

[Meral Beksac @mbeksac56]

⁦@EMN_EuMMnet⁩ ⁦@RahulBanerjeeMD⁩ ⁦@HDMyeloma⁩ CGS is not able to predict functional high risk ⁦@TheEBMT⁩

[Anna-Lena Neehus @ALNeehus]

Excited to share our latest work published today in @NatImmunol! 🎉 Together with Taja Vatovec, we investigated how somatic CBL deficiency affects B cell development and function. https://t.co/sROc3oMXX2

[Sam Rodriques @SGRodriques]

We're launching integrations for Kosmos today that allow it to access 80% of publicly available biology data.

This means it can now find its own data to initiate projects, enrich its investigation with data from different modalities, and validate its findings in alternative datasets.

We've seen runs where it will come up with a finding, try to replicate it in other datasets, fail, and then iterate on its hypothesis until it finds something more robust. In our blog post (link below), we describe how Kosmos was able to take a finding about TGFb signaling and the extracellular matrix in pancreatic cancer from bulk RNAseq and enrich it with further analysis in human clinical data and single cell data that it grabbed autonomously. This allowed it to come up with a plausible mechanism for its initial finding using other datasets, all without human intervention. In our testing so far, it seems like a very significant unlock.

Read about it on our blog (link below), and try it on our website. Academics get three free runs per month. (It's also now way easier to try, since you don't have to have a dataset at hand to get Kosmos to do really interesting analysis.)

[Nature Medicine @NatureMedicine]

Genomic and transcriptomic analysis of samples from patients with multiple myeloma, followed by in vitro validation, indicate mechanisms of antigen escape in response to GPRC5D T cell engager talquetamab, including biallelic deletions, small nucleotide variants and insertion-deletions and chromatin silencing.
https://t.co/fryIkDlXdj

[nizar jacques bahlis @NBahlis]

Delighted to share a MonumenTal work led by Dr Holly Lee @hollyleeYJ and many collaborations detailing the multimodal resistance mechanisms to anti-GPRC5D TCE in multiple myeloma out today in @NatureMedicine https://t.co/rGNFlfSAln @UCalgaryMed @Charb_Cancer #msmm (1/12)

[James Zou @james_y_zou]

Today in @NatureMedicine we report that AI can predict 130 diseases from 1 night of sleep🛌

We trained a foundation model (#SleepFM) on 585K hours of sleep recordings from 65K people—brain, heart, muscle & breathing signals combined.

AI learns the language of sleep🧵

[Lucie Laplane @LucieLaplane]

Our paper on clonal evolution is out in @NatureRevCancer
The output of a cool collaboration with @cmaley
We searched for where and how progress could be made in our understanding of evolutionary dynamics in cancers.
https://t.co/CGQFUseIu9
Thanks Carlo for this collab!

[Ben Derman @bdermanmd]

TecLille: Tec+Dara in transplant ineligible NDMM
n=37; median age 73 (!)
Very high MRD negativity rates even at 6 months!
Very interesting correlatives, including clonotypic peptide sequencing and sBCMA.
No progressions. No deaths.
14% grade 3+ infections (nearly everyone got IVIg starting within first cycle).

If this regimen can be so well tolerated upfront even in older adults, that bodes very well for the future of bispecific antibodies in frontline therapy.

[Rakesh Popat @DrRakeshPopat]

Tec Dara for transplant ineligible newly diagnosed myeloma. Very impressive results with early step down to Q4W Tec dosing and high IVIG use to make tolerable. Good to hear that plans to move to Q8w Tec and fixed duration #ASH25

[Bruno Paiva @BrunoPaiva_UNAV]

#ASH2025 first of three abstracts from the European CTC consortium #mmsm

@Dagostino_MD shows how CTCs are complementary to the R2-ISS and IMS/IMWG genomic risk score, supporting the future integration of CTCs in myeloma staging!
@LucaBertamini
@TomasJelinekMD
@DZihala

[Daniela Cerezo Wallis @danielacerezo]

I’m thrilled to introduce you to the NeuMap! our latest work in @Nature. A global, comprehensive, single-cell transcriptional atlas of neutrophils across 47 biological conditions in human and mice. A real tour-de-force 🗺️ @AndrsHidalgo16 https://t.co/W8X6eOUsKc

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Comprehensive characterization of multiple myeloma genomes from BM or PB w/ novel clinical assay [GenoPredicta] = ID of resistance mechanisms [Nov 3, 2025] @BrunoPaiva_UNAV et al @myelomaMD #ASH25 abs25-14403 PID2586 https://t.co/6jbiTS6Aa9 #mmsm #cagenome #oncopath #LiquidBiopsy

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Ph2 teclistamab [BCMA BsA] + daratumumab in elderly Pts w/ TI NDMM: IFM2021-01 TecLILLE trial Cohort A (Tec-Dara) [Nov 3, 2025] Manier et al. #ASH25 abs25-10098 PID 367 https://t.co/JDTxuk0shF #NCT05572229 #mmsm #IDonc #geriheme n=37, ORR 100%, 97% >=VGPR

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: ID2 suppresses multiple myeloma cell proliferation by repressing the activity of the transcription factor TCF3; BM milieu supports this by further decreasing ID2 expression & enhancing TCF3 activity, partly via IL-6: https://t.co/B2b4LGGAEG. #mmsm